HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tremblay, F. Articles by Roden, M. Search for Related Content PubMed PubMed Citation Articles by Tremblay, F. Articles by Roden, M. Social Bookmarking                What's this?

Overactivation of S6 Kinase 1 as a Cause of Human Insulin Resistance During Increased Amino Acid Availability

¹ Department of Physiology and Lipid Research Unit, Laval University Hospital Research Center, Ste-Foy, Québec, Canada
² Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
³ Department of Surgery, Medical University of Vienna,Vienna, Austria
⁴ 1. Medical Department, Hanusch Hospital, Vienna, Austria

To examine the molecular mechanisms by which plasma amino acid elevation impairs insulin action, we studied seven healthy men twice in random order during infusion of an amino acid mixture or saline (total plasma amino acid 6 vs. 2 mmol/l). Somatostatin-insulin-glucose clamps created conditions of low peripheral hyperinsulinemia (100 pmol/l, 0–180 min) and prandial-like peripheral hyperinsulinemia (430 pmol/l, 180–360 min). At low peripheral hyperinsulinemia, endogenous glucose production (EGP) did not change during amino acid infusion but decreased by 70% during saline infusion (EGP_{150–180 min} 11 ± 1 vs. 3 ± 1 µmol · kg^–1 · min^–1, P = 0.001). Prandial-like peripheral hyperinsulinemia completely suppressed EGP during both protocols, whereas whole-body rate of glucose disappearance (R_d) was 33% lower during amino acid infusion (R_{d 330–360 min} 50 ± 4 vs. 75 ± 6 µmol · kg^–1 · min^–1, P = 0.002) indicating insulin resistance. In skeletal muscle biopsies taken before and after prandial-like peripheral hyperinsulinemia, plasma amino acid elevation markedly increased the ability of insulin to activate S6 kinase 1 compared with saline infusion (3.7- vs. 1.9-fold over baseline). Furthermore, amino acid infusion increased the inhibitory insulin receptor substrate-1 phosphorylation at Ser312 and Ser636/639 and decreased insulin-induced phosphoinositide 3-kinase activity. However, plasma amino acid elevation failed to reduce insulin-induced Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation. In conclusion, amino acids impair 1) insulin-mediated suppression of glucose production and 2) insulin-stimulated glucose disposal in skeletal muscle. Our results suggest that overactivation of the mammalian target of rapamycin/S6 kinase 1 pathway and inhibitory serine phosphorylation of insulin receptor substrate-1 underlie the impairment of insulin action in amino acid–infused humans.

Abbreviations: 4E-BP1, eukaryotic initiation factor 4E–binding protein 1; EGP, endogenous glucose production; FFA, free fatty acid; GSK, glycogen synthase kinase; IRS, insulin receptor substrate; MEM, minimum essential medium; mTOR, mammalian target of rapamycin; PI, phosphoinositide; PKB, protein kinase B; S6K1, S6 kinase 1

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Fraenkel, M. Ketzinel-Gilad, Y. Ariav, O. Pappo, M. Karaca, J. Castel, M.-F. Berthault, C. Magnan, E. Cerasi, N. Kaiser, et al. mTOR Inhibition by Rapamycin Prevents {beta}-Cell Adaptation to Hyperglycemia and Exacerbates the Metabolic State in Type 2 Diabetes Diabetes, April 1, 2008; 57(4): 945 - 957. [Abstract] [Full Text] [PDF]

				V. Ouellet, J. Marois, S. J. Weisnagel, and H. Jacques Dietary Cod Protein Improves Insulin Sensitivity in Insulin-Resistant Men and Women: A randomized controlled trial Diabetes Care, November 1, 2007; 30(11): 2816 - 2821. [Abstract] [Full Text] [PDF]

				F. Tremblay, S. Brule, S. Hee Um, Y. Li, K. Masuda, M. Roden, X. J. Sun, M. Krebs, R. D. Polakiewicz, G. Thomas, et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance PNAS, August 28, 2007; 104(35): 14056 - 14061. [Abstract] [Full Text] [PDF]

				M. Krebs, B. Brunmair, A. Brehm, M. Artwohl, J. Szendroedi, P. Nowotny, E. Roth, C. Furnsinn, M. Promintzer, C. Anderwald, et al. The Mammalian Target of Rapamycin Pathway Regulates Nutrient-Sensitive Glucose Uptake in Man Diabetes, June 1, 2007; 56(6): 1600 - 1607. [Abstract] [Full Text] [PDF]

				K. Morino, K. F. Petersen, and G. I. Shulman Molecular Mechanisms of Insulin Resistance in Humans and Their Potential Links With Mitochondrial Dysfunction Diabetes, December 1, 2006; 55(Supplement_2): S9 - S15. [Abstract] [Full Text] [PDF]

				B. Draznin Molecular Mechanisms of Insulin Resistance: Serine Phosphorylation of Insulin Receptor Substrate-1 and Increased Expression of p85{alpha}: The Two Sides of a Coin. Diabetes, August 1, 2006; 55(8): 2392 - 2397. [Abstract] [Full Text] [PDF]